Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
| Revenue (TTM) | $87.53M |
| Gross Profit (TTM) | $76.71M |
| EBITDA | $-158.65M |
| Operating Margin | -81.60% |
| Return on Equity | -471.20% |
| Return on Assets | -49.60% |
| Revenue/Share (TTM) | $0.98 |
| Book Value | $0.93 |
| Price-to-Book | 14.81 |
| Price-to-Sales (TTM) | 8.01 |
| EV/Revenue | 7.86 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1775.00% |
| Shares Outstanding | $90.56M |
| Float | $70.57M |
| % Insiders | 1.02% |
| % Institutions | 110.91% |
Volatility is currently expanding
Verastem NASDAQ: VSTM executives outlined the company's commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic, lung and colorectal cancers.
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical upd.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET H.C. Wainwright Annual Global Investment Confer.
Verastem is evolving from a speculative biotech into a commercially validated precision oncology company, leveraging AVMAPKI FAKZYNJA revenue to fund KRAS G12D programs. VSTM's AVMAPKI FAKZYNJA launch demonstrates strong product-market fit, with $43.7M H1 2026 revenue and growing prescriber adoption in a rare disease market. The October 2026 VS-7375 data update is a pivotal catalyst; positive results could unlock multibillion-dollar KRAS G12D markets in pancreatic, lung, and colorectal cancer.
Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investo.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VSTM and any ticker you trade — then tracks every position and per-strategy win rate.
